Literature DB >> 17937829

Coverage with evidence development: an examination of conceptual and policy issues.

John Hutton1, Paul Trueman, Christopher Henshall.   

Abstract

The application of conditionality to coverage decisions for healthcare technologies is increasing. Coverage with Evidence Development (CED) represents a specific approach to coverage for promising technologies for which the evidence remains uncertain. CED demands that additional evidence is generated to address the sources of uncertainty and secure ongoing coverage. This study explores the conceptual and policy issues relating to CED and discusses issues involved in operationalizing CED in practice, including presenting criteria for which technologies may be most suitable for CED. This study is intended to further the debate on the use of CED as well as highlight areas that warrant further research.

Entities:  

Mesh:

Year:  2007        PMID: 17937829     DOI: 10.1017/S0266462307070651

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  26 in total

Review 1.  International comparison of comparative effectiveness research in five jurisdictions: insights for the US.

Authors:  Adrian R Levy; Craig Mitton; Karissa M Johnston; Brian Harrigan; Andrew H Briggs
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 2.  Challenges of translating genetic tests into clinical and public health practice.

Authors:  Wolf H Rogowski; Scott D Grosse; Muin J Khoury
Journal:  Nat Rev Genet       Date:  2009-07       Impact factor: 53.242

Review 3.  New challenges to medicare beneficiary access to mAbs.

Authors:  Joshua Cohen; Andrew Wilson
Journal:  MAbs       Date:  2009 Jan-Feb       Impact factor: 5.857

4.  Access with evidence development in the UK: past experience, current initiatives and future potential.

Authors:  Andrew Briggs; Karen Ritchie; Elisabeth Fenwick; Kalipso Chalkidou; Peter Littlejohns
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 5.  Review on early technology assessments of nanotechnologies in oncology.

Authors:  Valesca P Retèl; Marjan J M Hummel; Wim H van Harten
Journal:  Mol Oncol       Date:  2009-05-20       Impact factor: 6.603

6.  NICE's 2008 Methods Guide: sensible consolidation or opportunities missed?

Authors:  Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

7.  When do performance-based risk-sharing arrangements make sense?

Authors:  Michael Drummond
Journal:  Eur J Health Econ       Date:  2015-07

Review 8.  Optimal global value of information trials: better aligning manufacturer and decision maker interests and enabling feasible risk sharing.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

9.  Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.

Authors:  Rena Conti; David L Veenstra; Katrina Armstrong; Lawrence J Lesko; Scott D Grosse
Journal:  Med Decis Making       Date:  2010-01-04       Impact factor: 2.583

10.  Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator.

Authors:  Mike Boggild; Jackie Palace; Pelham Barton; Yoav Ben-Shlomo; Thomas Bregenzer; Charles Dobson; Richard Gray
Journal:  BMJ       Date:  2009-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.